NO20062193L - Bisykliske [3.1.0] derivater som glysintransportorinhibitorer - Google Patents

Bisykliske [3.1.0] derivater som glysintransportorinhibitorer

Info

Publication number
NO20062193L
NO20062193L NO20062193A NO20062193A NO20062193L NO 20062193 L NO20062193 L NO 20062193L NO 20062193 A NO20062193 A NO 20062193A NO 20062193 A NO20062193 A NO 20062193A NO 20062193 L NO20062193 L NO 20062193L
Authority
NO
Norway
Prior art keywords
bicyclic
derivatives
transporter inhibitors
glycine transporter
psychoses
Prior art date
Application number
NO20062193A
Other languages
English (en)
Other versions
NO337361B1 (no
Inventor
John Lowe
Stan Mchardy
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34465157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062193(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NO20062193L publication Critical patent/NO20062193L/no
Publication of NO337361B1 publication Critical patent/NO337361B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår en serie av substituerte bicykliske [3.1.0]aminer med formel I: hvori A, B, D, Q, V, W, X, Y, Z, R2, R3, R4, R5, R14, R15, R30. o, p, s, t og q er som definert i beskrivelsen, deres farmasøytisk akseptable salter, farmasøytiske sammensetninger derav og deres anvendelse for å forbedre kognisjon og behandling av positive og negative symptomer på schizofreni og andre psykoser hos pattedyr, som inkluderer mennesker.
NO20062193A 2003-10-14 2006-05-15 Bicykliske[3.1.0] derivater som glysintransportørinhibitorer, og farmasøytiske sammensetninger inneholdende slike. NO337361B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51084603P 2003-10-14 2003-10-14
PCT/US2004/034083 WO2005037216A2 (en) 2003-10-14 2004-10-14 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors

Publications (2)

Publication Number Publication Date
NO20062193L true NO20062193L (no) 2006-05-15
NO337361B1 NO337361B1 (no) 2016-03-29

Family

ID=34465157

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062193A NO337361B1 (no) 2003-10-14 2006-05-15 Bicykliske[3.1.0] derivater som glysintransportørinhibitorer, og farmasøytiske sammensetninger inneholdende slike.

Country Status (26)

Country Link
US (1) US7473787B2 (no)
EP (1) EP1680124B1 (no)
JP (2) JP4732354B2 (no)
KR (1) KR20060095865A (no)
CN (2) CN101838271A (no)
AP (1) AP2006003592A0 (no)
AU (1) AU2004281794B2 (no)
BR (1) BRPI0415356A (no)
CA (1) CA2542279C (no)
CR (2) CR8333A (no)
DK (1) DK1680124T3 (no)
EA (1) EA009903B1 (no)
EC (1) ECSP066504A (no)
ES (1) ES2634841T3 (no)
GE (1) GEP20104959B (no)
IL (1) IL174299A (no)
IS (1) IS8355A (no)
MA (1) MA28094A1 (no)
MX (1) MXPA06004279A (no)
NO (1) NO337361B1 (no)
NZ (1) NZ546012A (no)
RS (1) RS20060190A (no)
TN (1) TNSN06109A1 (no)
UA (1) UA86037C2 (no)
WO (1) WO2005037216A2 (no)
ZA (1) ZA200602174B (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO339422B1 (no) * 2005-04-08 2016-12-12 Pfizer Prod Inc Bisykliske [3.0.1]heteroarylamider som type 1 glysin transport inhibitorer

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ546012A (en) * 2003-10-14 2009-12-24 Pfizer Prod Inc Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
GB0408774D0 (en) * 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
GB0408772D0 (en) * 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
US7750158B2 (en) 2004-06-22 2010-07-06 Schering Corporation Cannabinoid receptor ligands
WO2007053498A1 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
US8067415B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007135527A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Benzimidazolyl compounds
WO2008065500A2 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
UA102379C2 (ru) * 2007-11-05 2013-07-10 Мерк Патент Гмбх Производные 7-азаиндола как селективные ингибиторы бета-гидроксистероида дегидрогеназы 1 типа
EP2378885A4 (en) * 2008-12-12 2013-01-02 Univ Vanderbilt GLYT1 BICYCLIC INHIBITORS AND METHODS OF MAKING AND USING THEM
KR20110117087A (ko) * 2008-12-29 2011-10-26 벤더르빌트 유니버시티 3.1.0 비시클릭 ｇｌｙｔ1 억제제 및 그것을 제조 및 사용하는 방법
FR2944283B1 (fr) * 2009-04-14 2011-05-06 Sanofi Aventis Derives de n-°(2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique
EP2409976A4 (en) 2009-03-19 2012-09-19 Taisho Pharmaceutical Co Ltd GLYCINTRANSPORTERHEMMER
WO2012036278A1 (ja) 2010-09-17 2012-03-22 大正製薬株式会社 グリシントランスポーター阻害物質
WO2012042539A2 (en) 2010-09-28 2012-04-05 Panacea Biotec Ltd Novel bicyclic compounds
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
CN103319645B (zh) * 2013-05-31 2016-08-10 南京洁雅新材料有限公司 一种水性金属保护剂及其生产工艺
EP3138843B1 (en) * 2014-04-28 2019-11-27 Medshine Discovery Inc. Isoquinolinesulfonyl derivative as rho kinase inhibitor
WO2017049172A1 (en) 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EP3350164A4 (en) * 2015-09-16 2019-03-27 Metacrine, Inc. X FARNESOID RECEPTOR AGONISTS AND USES THEREOF
EP3350166A4 (en) 2015-09-16 2019-05-01 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
DK3350165T3 (da) 2015-09-16 2023-09-25 Organovo Inc Farnesoid-X-receptoragonister og anvendelser deraf
EA202192925A1 (ru) * 2019-05-01 2022-03-23 Бёрингер Ингельхайм Интернациональ Гмбх Твердые формы ингибитора glyt1
CN114502540A (zh) 2019-05-31 2022-05-13 医肯纳肿瘤学公司 Tead抑制剂和其用途
MX2021014443A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
AR127055A1 (es) 2021-09-14 2023-12-13 Lilly Co Eli Sales agonistas de sstr4

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL329195A1 (en) * 1996-03-29 1999-03-15 Pfizer Derivatives of 6-phenylpyridol-2-amine
DK1014966T3 (da) * 1996-05-31 2006-12-04 Allelix Neuroscience Inc Farmaceutisk præparat til behandling af neurologiske og neuropsykiatriske lidelser
ES2248633T3 (es) * 2001-04-17 2006-03-16 MERCK & CO., INC. Antibioticos oxazolidinona que contienen biciclo (3,1,o)hexano y derivados de los mismos.
SI1440059T1 (sl) * 2001-10-22 2008-08-31 Pfizer Prod Inc Derivati 3-azabiciklo(3.1.0)heksana kot antagonisti opioidnega receptorja
WO2003037865A1 (en) 2001-10-31 2003-05-08 Morphochem Aktiengesellschaft für kombinatorische Chemie Novel anticancer compounds
GB0130696D0 (en) * 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
MXPA05000434A (es) * 2002-07-08 2005-04-19 Ranbaxy Lab Ltd Derivados de hexano [3.1.0] azabiciclo 3,6-disustituido utiles como antagonistas de receptor muscarinico.
EP1534675B1 (en) * 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo¬3.1.0 hexane derivatives as muscarinic receptor antagonists
CN100436414C (zh) * 2003-04-11 2008-11-26 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
NZ546012A (en) * 2003-10-14 2009-12-24 Pfizer Prod Inc Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
BRPI0415459A (pt) * 2003-10-16 2006-12-19 Pfizer Prod Inc preparação de derivados de 3-azabiciclo[3.1.0]hexano
CN106434833A (zh) 2004-05-23 2017-02-22 杰勒德·M·豪斯 Theramutein调节剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO339422B1 (no) * 2005-04-08 2016-12-12 Pfizer Prod Inc Bisykliske [3.0.1]heteroarylamider som type 1 glysin transport inhibitorer

Also Published As

Publication number Publication date
NZ546012A (en) 2009-12-24
NO337361B1 (no) 2016-03-29
UA86037C2 (ru) 2009-03-25
CA2542279A1 (en) 2005-04-28
BRPI0415356A (pt) 2006-12-12
CR8333A (es) 2007-08-14
CR20110095A (es) 2011-03-09
MXPA06004279A (es) 2006-06-28
ECSP066504A (es) 2006-10-10
US7473787B2 (en) 2009-01-06
IL174299A (en) 2011-12-29
IL174299A0 (en) 2006-08-01
EP1680124A2 (en) 2006-07-19
EP1680124B1 (en) 2017-05-31
DK1680124T3 (en) 2017-08-21
CN1867338A (zh) 2006-11-22
EA200600513A1 (ru) 2006-08-25
CA2542279C (en) 2011-08-09
EA009903B1 (ru) 2008-04-28
GEP20104959B (en) 2010-04-26
WO2005037216A3 (en) 2005-08-04
WO2005037216A2 (en) 2005-04-28
TNSN06109A1 (fr) 2007-11-15
US20050096375A1 (en) 2005-05-05
AU2004281794A1 (en) 2005-04-28
CN101838271A (zh) 2010-09-22
JP2007508374A (ja) 2007-04-05
JP2011157358A (ja) 2011-08-18
AP2006003592A0 (en) 2006-04-30
EP1680124A4 (en) 2009-05-13
IS8355A (is) 2006-03-16
KR20060095865A (ko) 2006-09-04
MA28094A1 (fr) 2006-08-01
ZA200602174B (en) 2007-04-25
ES2634841T3 (es) 2017-09-29
JP4732354B2 (ja) 2011-07-27
RS20060190A (en) 2008-08-07
AU2004281794B2 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
NO20062193L (no) Bisykliske [3.1.0] derivater som glysintransportorinhibitorer
NO20051826L (no) Heterosyklisk substituerte piperaziner for behandling av schizofreni
EA200701902A1 (ru) Бициклические [3.1.0] гетероариламиды в качестве ингибиторов переноса глицина типа i
NO20056007L (no) Dobbel NK1/NK3 antagonister for behandling av schizofreni
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
HUP0203122A2 (hu) Fab I inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE602005023015D1 (de) Indolderivate als viruzide
GEP20074055B (en) Nicotinamide derivatives useful as pde4 inhibitors
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
BG66094B1 (bg) Азабициклени съединения, тяхното получаване и използване като лекарствени средста, по-специално като антибактериални средства
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
UY27368A1 (es) Nuevos compuestos
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20052493L (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
ATE428422T1 (de) Piperidin-derivate als ccr3-antagonisten
RS101304A (sr) Indolni, azaindolni i srodni heterociklični 4-alkenil piperidinski amidi
FI970317A (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
ATE374773T1 (de) Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: PFIZER PRODUCTS INC, US

MM1K Lapsed by not paying the annual fees